(IN BRIEF) Simon Linder, a PhD candidate, conducted multi-omics research to understand how tumor cells adapt to hormonal therapies in prostate cancer. Prostate cancer is hormone-dependent, and although hormonal therapy is initially effective, cancer cells eventually become resistant to it. … Read the full press release
Posted in Business, Education, Healthcare, Management, Netherlands, News, Science
Tagged hormonal therapy, Multi-Omics Research, prostate cancer, protein, Resistance, Simon Linder, treatment, TU/e, Wilbert Zwart
Not intended for U.S. and UK Media (IN BRIEF) The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended darolutamide, an oral androgen receptor inhibitor, for marketing authorization in the European Union as a treatment for patients … Read the full press release
Posted in European Union, Germany, Healthcare, News, Pharma & Biotech
Tagged ADT, androgen deprivation therapy, Bayer, CHMP, Christine Roth, darolutamide, docetaxel, European Commission, European Medicines Agency, inhibitor, metastatic hormone-sensitive prostate cancer, mHSP, nmCRPC, Nubeqa™, Prof. Bertrand Tombal, prostate cancer
(PRESS RELEASE) CAMBRIDGE, 24-Sep-2021 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British–Swedish multinational pharmaceutical and biopharmaceutical company, has announced positive high-level results from the PROpel Phase III trial showed AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone demonstrated a … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged abiraterone, AstraZeneca, Cancer, chemotherapy, Eastern Cooperative Oncology Group, EcoG, hormones, HRR, IDMC, Independent Data Monitoring Committee, Lynparza, mCRPC, MSD, MSD Research Laboratories, Olaparib, PARP, PROpel Phase III, prostate cancer, Roy Baynes, rPFS, Susan Galbraith
(PRESS RELEASE) FREIBURG, Germany, 1-Jul-2021 — /EuropaWire/ — Prostate cancer is the second most common cancer. According to the American Cancer Association, 1 in every 8 men will be diagnosed with it in their lifetime. In 2018 around 1.2 million … Read the full press release
Posted in Business, Germany, Healthcare, Investment, News, Pharma & Biotech, Science
Tagged American Cancer Association, B66, bioscience, Biotech, bladder, breast, Cancer, colorectal, Dr Eric Metzger, Freiburg, Germany, histone methyltransferase, inhibitors, KMT9, lung cancer, Manfred Jung, Mike Dunckley, pharma, Professor Manfred Jung, Professor Roland Schule, Professors Roland Schule, prostate cancer, prostate tumours, University of Freiburg
DUNDEE, 03-Jul-2018 — /EuropaWire/ — We have won Research Project of the Year and the Enhanced Student Learning Awards at the Herald Higher Education Awards, held last night in Glasgow. Professor Ghulam Nabi’s work on prostate cancer research was named Research … Read the full press release
Researchers at KTH and Karolinska Institutet have concluded that AI can contribute to increased understanding of how prostate cancer develops, and even improve clinical diagnosis and treatment of the disease. STOCKHOLM, 28-Jun-2018 — /EuropaWire/ — Every cancer tumor is unique, … Read the full press release
Posted in Education, Healthcare, Science, Sweden, Technology
Tagged AI, Cancer, David Callahan, Emilie Berglund, Håkan Soold, heterogeneity, Joakim Lundeberg, Karolinska Institutet, KTH, metastases, prostate, prostate cancer
Umeå, Sweden, 14-Jul-2016 — /EuropaWire/ — For the first time, researchers at Umeå University and Lund University have estimated the risk of developing various types of prostate cancer for men with the disease in the family. Men with brothers who have … Read the full press release
Posted in Education, Healthcare, Science, Sweden
Tagged Lund University, Ola Bratt, prostate cancer, Umeå University
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
